Pharmacokinetic study of TRK-820 -Pharmacokinetic study among TRK-820 tablets and TRK-820 soft capsules.-

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1080221878

Enrollment

Registered

2012-08-07

Start date

2012-08-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Japanese Male

Interventions

investigational material(s) Generic name etc : TRK-820T INN of investigational material : nalfurafine Therapeutic category code : 119 Other agents affecting central nervous system Dosage and Administr

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Subjects over 20 and under 40 years of age. Subjects giving consent to enter the clinical trial.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Evaluation of pharmacokinetics. Measurement of unaltered TRK-820 concentration in plasma and calculation of pharmacokinetic parameters.	—

Secondary

Measure	Time frame
Evaluation of safety. Adverse Event(AE), Adverse Drug Reaction(ADR), Clinical Test, Vital Sign(VS), Electrocardiogram(ECG)(12-lead)	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026